Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Fera…
Industry Peers
Drug Manufacturers - Specialty & Generic| Headline | Source | Time |
|---|---|---|
Yesterday | ||
 Shield Therapeutics jumps 11% as losses narrow and profitability target held Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) rose 11% to 4.89p on Thursday after the pharmaceutical company reported sharply narrower half-year losses and reaffirmed its aim of reaching operating profitability in 2026. Peel Hunt reiterated its 'buy' rating and 15p price target,... | ||
Older | ||
YYahoo Finance Singapore | ||
 ProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for Rilparencel ProKidney Corp. (NASDAQ:PROK) is one of the best biotech penny stocks to buy in 2026. On March 25, ProKidney appointed Greg Madison as Chief Commercial Officer, a move aimed at preparing the company for the potential launch of its lead cell therapy, rilparencel. Reporting to CEO Bruce Culleton, M.D., Madison is tasked with shaping the […] | IInsider Monkey | |
 Shield Therapeutics drops as CFO exits and Medicaid concerns weigh Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) fell 12% to 7.71p after the group reported first-quarter revenue growth and positive earnings but flagged potential headwinds in the US market and announced the departure of its finance chief. The pharmaceutical company, which focuses... | ||
 Shield shares jump after FDA extends Accrufer exclusivity Broker Cavendish says additional US protection strengthens long-term outlook and reiterates buy rating. Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) jumped as much 11% earlier in the session after the company said US regulators had granted an additional three years of data... | ||
TThe Twelfth Magpie | ||
 When Will Shield Therapeutics plc (LON:STX) Breakeven? We feel now is a pretty good time to analyse Shield Therapeutics plc's ( LON:STX ) business as it appears the company... | ||
Shield Therapeutics (LON:STX) jumps 22% this week, taking one-year gains to 110% Unless you borrow money to invest, the potential losses are limited. On the other hand, if you find a high quality... | ||
 Shield Therapeutics First Half 2025 Earnings: US$0.009 loss per share (vs US$0.02 loss in 1H 2024) Shield Therapeutics ( LON:STX ) First Half 2025 Results Key Financial Results Revenue: US$21.4m (up 77% from 1H 2024... | ||